Elan news from FierceBiotech
News
FDA holds back approval for J&J schizophrenia med
The FDA has put up at least a temporary roadblock to J&J's schizophrenia drug paliperidone palmitate. A once-monthly injectable with the same active ingredient as Invega, a newly approved Read more...
Cinven drops out of bidding for Elan division
The bidding war for Elan Drug Technologies, a division of the big Irish biotech, just lost a key player. The private equity player Cinven has dropped out of the auction, leaving Bain Capital and TPG. Read more...
Elan considers selling division
Ireland's Elan is considering selling its development and manufacturing division for around $1.5 billion, a move that would leave the company devoted to its bio-pharmaceuticals business. Read more...
Alzheimer's drug results boost Elan, Wyeth
Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical Read more...
Elan wins $55M judgment in patent scrap
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Read more...
Icahn accuses Biogen of lying about sales process
Hell hath no fury like Icahn scorned. Frustrated by Biogen Idec's decision to take itself off the Read more...
$117M venture firm takes flight in Europe
A group of Elan veterans in Ireland have launched a €75 million ($117 million) venture fund for life sciences companies. Fountain Healthcare Partners, based in Dublin, plans to sink anywhere from Read more...
Wyeth, Elan suspend Alzheimer's vaccine study
Wyeth and Elan have suspended dosing patients in a mid-stage study of the experimental Alzheimer's vaccine ACC-001 after seeing one of the patients in the study develop skin lesions. Studies of Read more...
Icahn aims for Biogen control
Carl Icahn says that Biogen Idec essentially ran a sham when it put itself up for auction Read more...
Biogen shares deflate as it gives up on sale
After ratcheting up expectations of a takeover and a hefty premium for stockholders, Biogen Idec pulled the rug out from Read more...
Get more Elan coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets